A study analyzing the FDA Adverse Events Reporting System found ipilimumab and nivolumab combination therapy to have the strongest association with uveitis, along with others which showed CTLA-4 inhibitors were associated with higher risks of anterior uveitis as related in Section 4. This evidence concerns the gene CTLA4 and anterior uveitis.